Tag #Drug Pricing

Showing 37 to 48 of 70 results

dailymail.co.uk

🌐 85% Global Worthiness

May 9, 22:11

Trump to Issue Executive Order Lowering Prescription Drug Prices

President Trump will sign an executive order next week to lower prescription drug prices by implementing a 'most favored nation' pricing model for Medicare, potentially saving billions and impacting millions of Americans while facing significant industry opposition.

Trump to Issue Executive Order Lowering Prescription Drug Prices

President Trump will sign an executive order next week to lower prescription drug prices by implementing a 'most favored nation' pricing model for Medicare, potentially saving billions and impacting millions of Americans while facing significant industry opposition.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the US healthcare system's structure contribute to the high cost of prescription drugs compared to other developed nations?

This executive order attempts to address the exorbitant cost of prescription drugs in the US, a cost significantly higher than in comparable countries. The current fragmented, privatized US healthcare system grants drugmakers substantial pricing power, resulting in prices up to 10 times higher than in countries with single-payer systems. By tying US prices to the lowest prices internationally, the administration seeks to correct this market imbalance.

theglobeandmail.com

🌐 85% Global Worthiness

May 5, 04:11

Competition Bureau Probes Express Scripts Canada Over Pharmacy Rebates

Canada's Competition Bureau is investigating Express Scripts Canada for potentially steering patients to certain pharmacies while charging excessive fees; the bureau is seeking information on rebates received by Express Scripts from drug manufacturers, wholesalers, and pharmacies to determine if ant...

Competition Bureau Probes Express Scripts Canada Over Pharmacy Rebates

Canada's Competition Bureau is investigating Express Scripts Canada for potentially steering patients to certain pharmacies while charging excessive fees; the bureau is seeking information on rebates received by Express Scripts from drug manufacturers, wholesalers, and pharmacies to determine if ant...

Progress

40% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

What specific anti-competitive practices is the Competition Bureau investigating regarding Express Scripts Canada, and what immediate consequences could result from these practices?

The Competition Bureau of Canada is investigating Express Scripts Canada, a major pharmacy benefit manager (PBM), for potential anti-competitive practices. The investigation centers on allegations that Express Scripts steers patients to specific pharmacies while charging those pharmacies excessive fees. The bureau is seeking information about rebates Express Scripts receives from drug manufacturers, wholesalers, and pharmacies, as this data may shed light on potential conflicts of interest.

forbes.com

🌐 85% Global Worthiness

May 2, 16:14

Trump Executive Order Seeks to Alter Medicare Drug Pricing, Faces Uphill Battle

President Trump signed an executive order potentially delaying small molecule drug price negotiations under the Inflation Reduction Act by up to four years, raising concerns about budget neutrality, legal challenges under the revised Chevron Doctrine, and political opposition.

Trump Executive Order Seeks to Alter Medicare Drug Pricing, Faces Uphill Battle

President Trump signed an executive order potentially delaying small molecule drug price negotiations under the Inflation Reduction Act by up to four years, raising concerns about budget neutrality, legal challenges under the revised Chevron Doctrine, and political opposition.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How might the executive order's attempt to modify the IRA's drug pricing provisions affect budget neutrality and cost savings?

The executive order seeks to address concerns within the pharmaceutical industry regarding uneven investment allocation between small and large molecule drugs caused by the differing eligibility timelines for price negotiation under the IRA. This four-year discrepancy favors large molecule drugs, potentially hindering innovation in small molecule treatments. The order's impact hinges on whether it can achieve budget neutrality, given the potential for reduced cost savings under the revised timeline.

elmundo.es

🌐 85% Global Worthiness

Apr 16, 04:09

Trump Executive Order Seeks to Lower Prescription Drug Prices

President Trump signed an executive order to lower prescription drug prices by modifying the Medicare drug price negotiation program, expediting generic approvals, increasing low-cost imports, and potentially reclassifying some drugs for over-the-counter sales, specifically mentioning insulin and ep...

Trump Executive Order Seeks to Lower Prescription Drug Prices

President Trump signed an executive order to lower prescription drug prices by modifying the Medicare drug price negotiation program, expediting generic approvals, increasing low-cost imports, and potentially reclassifying some drugs for over-the-counter sales, specifically mentioning insulin and ep...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How might the proposed changes to the Medicare drug negotiation program influence pharmaceutical innovation and investment decisions?

This executive order seeks to address high prescription drug costs by altering the Medicare drug price negotiation program, which includes a provision limiting drug prices. Trump argues this 'penalty' discourages investment in cheaper, commonly used drugs, shifting investment towards more expensive biologics. The order also focuses on streamlining generic approvals and increasing low-cost drug imports.

us.cnn.com

🌐 85% Global Worthiness

Apr 5, 04:11

Trump Administration Blocks Expansion of Anti-Obesity Drug Coverage

The Trump administration blocked a Biden plan to expand coverage of costly anti-obesity drugs to over 7 million Medicare and Medicaid beneficiaries, citing cost concerns and the need for further review, despite potential benefits and growing adoption by some states.

Trump Administration Blocks Expansion of Anti-Obesity Drug Coverage

The Trump administration blocked a Biden plan to expand coverage of costly anti-obesity drugs to over 7 million Medicare and Medicaid beneficiaries, citing cost concerns and the need for further review, despite potential benefits and growing adoption by some states.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential long-term implications of this decision for patients, healthcare providers, and the broader healthcare system?

The long-term impact of this decision is uncertain. While some patients may gain coverage through other medical conditions treated by these drugs, many remain without access due to the high cost. This underscores the need for broader policy discussions regarding drug pricing and chronic disease management, specifically highlighting the limitations and fiscal constraints of both public and private healthcare provision in the US.

welt.de

🌐 75% Global Worthiness

Apr 2, 16:09

Boehringer Ingelheim's 2024 Sales Surge Driven by Jardiance, but US Pricing and EU Regulations Pose Challenges

Boehringer Ingelheim reported €21.9 billion in human pharmaceutical sales in 2024, a 7% increase year-over-year, driven by Jardiance (€8.4 billion), while animal health sales reached €4.7 billion, with Nexgard (€1.35 billion) leading the growth; the company invested €6.2 billion in R&D and anticipat...

Boehringer Ingelheim's 2024 Sales Surge Driven by Jardiance, but US Pricing and EU Regulations Pose Challenges

Boehringer Ingelheim reported €21.9 billion in human pharmaceutical sales in 2024, a 7% increase year-over-year, driven by Jardiance (€8.4 billion), while animal health sales reached €4.7 billion, with Nexgard (€1.35 billion) leading the growth; the company invested €6.2 billion in R&D and anticipat...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the key financial results for Boehringer Ingelheim in 2024, and what factors drove this performance?

Boehringer Ingelheim reported a 7% increase in human pharmaceutical sales to €21.9 billion in 2024, driven by a 14%+ surge in Jardiance sales to €8.4 billion. Animal health sales also grew by 1.9% to €4.7 billion, with Nexgard sales increasing by 14% to €1.35 billion. The company invested €6.2 billion in R&D, anticipating several new product launches, potentially two in 2025.

forbes.com

🌐 85% Global Worthiness

May 6, 01:16

CVS Drops Eli Lilly's Zepbound from Preferred Formulary

CVS Health will remove Eli Lilly's weight-loss drug Zepbound from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy; this impacts 90 million CVS Caremark members and highlights the power of PBMs in shaping drug access and affordability.

CVS Drops Eli Lilly's Zepbound from Preferred Formulary

CVS Health will remove Eli Lilly's weight-loss drug Zepbound from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy; this impacts 90 million CVS Caremark members and highlights the power of PBMs in shaping drug access and affordability.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of CVS Health's decision to remove Zepbound from its preferred formulary on patient access and affordability?

CVS Health will remove Eli Lilly's weight-loss drug, Zepbound, from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy instead. This impacts 90 million CVS Caremark members, potentially limiting Zepbound access or increasing out-of-pocket costs for many. Lilly is mitigating this by offering Zepbound through its own direct-to-consumer pharmacy and telehealth partnerships, bypassing traditional gatekeepers.

forbes.com

🌐 85% Global Worthiness

May 4, 04:10

Trump's MFN Drug Pricing Proposal: A Recipe for Reduced Access and Innovation

President Trump's proposed MFN policy for Medicaid drug pricing, mirroring the lowest prices in other developed nations, would severely reduce access to new medicines and hinder pharmaceutical innovation in the U.S., as those countries have price controls resulting in limited drug availability and s...

Trump's MFN Drug Pricing Proposal: A Recipe for Reduced Access and Innovation

President Trump's proposed MFN policy for Medicaid drug pricing, mirroring the lowest prices in other developed nations, would severely reduce access to new medicines and hinder pharmaceutical innovation in the U.S., as those countries have price controls resulting in limited drug availability and s...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of implementing the proposed MFN policy on drug pricing in the U.S.?

President Trump's proposed MFN policy for Medicaid drug pricing, adopting the lowest prices from other developed countries, would worsen the current situation by reducing drug availability and innovation. This policy outsources U.S. healthcare policy to countries with strict price controls, resulting in limited access to new medicines.

theglobeandmail.com

🌐 85% Global Worthiness

May 1, 16:13

Eli Lilly Q1 Earnings Beat Expectations Despite Zepbound Reimbursement Setback

Eli Lilly exceeded Q1 2024 earnings expectations with \$12.73 billion in revenue and \$3.34 adjusted EPS, but CVS's removal of Zepbound from its formulary, starting July 1, caused a 5 percent stock drop due to price competition with Novo Nordisk's Wegovy; Lilly holds a 53.3 percent U.S. market share...

Eli Lilly Q1 Earnings Beat Expectations Despite Zepbound Reimbursement Setback

Eli Lilly exceeded Q1 2024 earnings expectations with \$12.73 billion in revenue and \$3.34 adjusted EPS, but CVS's removal of Zepbound from its formulary, starting July 1, caused a 5 percent stock drop due to price competition with Novo Nordisk's Wegovy; Lilly holds a 53.3 percent U.S. market share...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary impact of CVS Health's decision to remove Eli Lilly's Zepbound from its reimbursement list?

Eli Lilly's Q1 2024 earnings surpassed expectations, reaching \$12.73 billion in revenue and \$3.34 in adjusted earnings per share. However, CVS Health's decision to remove Zepbound from its reimbursement list, effective July 1, caused a 5 percent drop in Lilly's stock price. This decision follows price negotiations between CVS and Novo Nordisk for Wegovy.

forbes.com

🌐 85% Global Worthiness

Apr 6, 22:10

Senate Advances Six Bills to Reform Drug Patent System

The Senate Judiciary Committee advanced six bipartisan bills to reform the drug patent system, aiming to curb anti-competitive practices like "patent thickets" and "product hopping" that inflate drug prices; the legislation's success remains uncertain due to past failures.

Senate Advances Six Bills to Reform Drug Patent System

The Senate Judiciary Committee advanced six bipartisan bills to reform the drug patent system, aiming to curb anti-competitive practices like "patent thickets" and "product hopping" that inflate drug prices; the legislation's success remains uncertain due to past failures.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the main tactics used by pharmaceutical companies to extend monopolies on brand-name drugs, and how do the proposed bills aim to address these?

The bills target practices that allow drug manufacturers to extend their patent protection beyond the original timeframe, thus impeding the market entry of cheaper generic and biosimilar drugs. This has resulted in significantly higher prices for many brand-name drugs in the US compared to other countries. The legislation seeks to create a more competitive market, benefiting consumers.

cnn.com

🌐 75% Global Worthiness

Apr 5, 04:11

Trump Administration Blocks Expansion of Anti-Obesity Drug Coverage

The Trump administration blocked a Biden plan to expand coverage of expensive anti-obesity drugs to over 7 million Americans on Medicare and Medicaid, citing potential fiscal impacts and the need for further review, leaving millions without access to these medications.

Trump Administration Blocks Expansion of Anti-Obesity Drug Coverage

The Trump administration blocked a Biden plan to expand coverage of expensive anti-obesity drugs to over 7 million Americans on Medicare and Medicaid, citing potential fiscal impacts and the need for further review, leaving millions without access to these medications.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did concerns regarding cost and fiscal impact influence the Trump administration's decision, and what role did state Medicaid agencies play?

The rejection reflects the Trump administration's focus on reducing federal spending, aligning with statements from both the administration and Elon Musk's Department of Government Efficiency. The Biden plan, costing an estimated $39.8 billion over a decade, faced significant opposition from state Medicaid agencies concerned about financial burdens. This decision maintains the status quo, where access to these expensive drugs is limited.

forbes.com

🌐 85% Global Worthiness

Mar 21, 16:11

Decreased Insurance Coverage for GLP-1 Agonists Amidst Soaring Demand

Between 2024 and 2025, insurance coverage for Ozempic dropped 22%, affecting 1.1 million people, while Zepbound saw a 14% increase in uninsured individuals (4.9 million), despite a 300% rise in Zepbound fills and doubled Ozempic fills since early 2024, highlighting the rising cost of these medicatio...

Decreased Insurance Coverage for GLP-1 Agonists Amidst Soaring Demand

Between 2024 and 2025, insurance coverage for Ozempic dropped 22%, affecting 1.1 million people, while Zepbound saw a 14% increase in uninsured individuals (4.9 million), despite a 300% rise in Zepbound fills and doubled Ozempic fills since early 2024, highlighting the rising cost of these medicatio...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the rising demand and high costs of GLP-1 agonists interact with insurance coverage trends?

The decreased insurance coverage correlates with rising demand for GLP-1 agonists like Ozempic and Zepbound, driven by their weight-loss effects. GoodRx data shows a 300% increase in Zepbound fills and a doubling of Ozempic fills since early 2024. This increase in demand, coupled with high costs (Ozempic: $997.58, Zepbound: $1086.37 per injection pen), creates financial strain for patients.

Showing 37 to 48 of 70 results